Only one of the 26 breast cancer patients was confirmed to have ER−/PR+ (ER: 5.5 units, PR: 6.1 units, HER2: 7.3 units) status by the Oncotype DX assay in our study. This evidence concerns the gene ERBB2 and breast carcinoma.